FibroGen, Inc. (FGEN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). Investors who purchased FibroGen securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether FibroGen has violated federal securities laws.
On June 26, 2023, FibroGen issued a press release “announc[ing] topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).” In the press release, the Company disclosed that the trial had failed to reach the primary or secondary endpoints and that “[b]ased on the results of ZEPHYRUS-1, ZEPHYRUS-2, the second Phase 3 clinical trial, will be discontinued.” On this news, FibroGen’s stock price fell $13.34 per share, or 83.12%, to close at $2.71 per share on June 26, 2023.
If you are aware of any facts relating to this investigation or purchased FibroGen shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.